Conduit Pharmaceuticals Inc. (CDT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.17 (-9.08%), Market cap $0.01B, 52-week low–high $0.39 ~ $9.35.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Phar
Financial statements, price targets, institutional (13F) holdings and related news for Conduit Pharmaceuticals Inc. are updated in real time on BlackAll Trade.
Conduit Pharmaceuticals Inc. trades at $0.17 (-9.08%). Real-time quotes and charts are available on BlackAll Trade.
Conduit Pharmaceuticals Inc. has a market cap of about $0.01B.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is